Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Drug-device combination products are therapeutic and diagnostic products including a drug and a medical device. Prefilled syringes, drug coated devices, and co-packages are some of the examples of traditional drug/device combination products.

The global drug-device combination products market is estimated to account for US$ 124.3 Bn in terms of value in 2020 and is expected to reach US$ 214.1 Bn by the end of 2027.

Global Drug-Device Combination Products Market: Drivers

Increasing prevalence of chronic disorders is expected to propel growth of the global drug-device combination products market over the forecast period. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.        

North America held dominant position in the global drug-device combination products market in 2019, accounting for 41.4% share in terms of value, followed by Europe and Asia Pacific, respectively

Figure 1. Global Drug-Device Combination Products Market Share (%), by Value, by Region, 2019

Drug-Device Combination Products  | Coherent Market Insights

Global Drug-Device Combination Products Market: Restraints

Drug-device combination products increase the risk of infections, which is expected to hinder growth of the market. Although stent infection is rare, it is associated with high morbidity and mortality. Drug eluting stents (DES) are associated with higher infection risk than bare metal stent (BMS), owing to their antiproliferative effects.

Moreover, presence of stringent and non-specific regulatory pathway for approval of Drug-device combination products is also expected to limit the market growth. There are separate regulatory approval pathways for pharmaceutical products and medical devices in the U.S. Investigational new drug (IND) application process is suited for pharmaceutical products, whereas medical devices fall under the investigational device exemption (IDE) pathway.

request-sample

Drug-Device Combination Products Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 115.0 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 8.1% 2027 Value Projection: US$ 214.1 Bn
Geographies covered (27):
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type: Drug Eluting Stents, Infusion pumps, Photosensitizers, Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements), Wound care combination products, Inhalers, Transdermal patches, Others( Intraocular implants, drug eluting beads)
Companies covered (8):

Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC

Growth Drivers:
  • Increasing prevalence of chronic diseases
  • New product approvals
Restraints & Challenges:
  • Risk of infections

Global Drug-Device Combination Products Market: Opportunities

Adoption of cloud-based data management software in combination products is expected to offer lucrative growth opportunities for players in the global drug-device combination products market. For instance, in January 2020, Medtronic plc launched Efficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, for effective management of targeted drug delivery pump.

Moreover, launch of generic combination products is also expected to aid in growth of the market. For instance, August 2019, Teva Pharmaceutical Industries Ltd. launched generic version of Mylan’s EpiPen for young children.

The global drug-device combination products market was valued at US$ 115.0 Bn in 2019 and is forecast to reach a value of US$ 214.1 Bn by 2027 at a CAGR of 8.1% between 2020 and 2027.

Figure 2. Global Drug-Device Combination Products Market Value (US$ Bn), and Y-o-Y Growth (%), 2019-2027

Drug-Device Combination Products  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2019, Becton, Dickinson and Company launched the BD Intevia 1mL two-step disposable auto-injector.

The market is witnessing higher preference for nasal sprays over auto injectors. For instance, in October 2019,            Bryn Pharma, LLC reported that patients prefer bi-dose epinephrine nasal spray over Epipen auto injector. The company presented the related data at the American Academy of Pediatrics (AAP) National Conference & Exhibition.

Global Drug-Device Combination Products Market: Competitive Landscape

Major players operating in the global drug-device combination products market include, Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC.

Global Drug-Device Combination Products Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, Flowonix Medical, Inc. received the U.S. Food and Drug Administration approval for its Prometra II Programmable Pump System for use with intrathecal baclofen. Prometra II Pump utilizes a pressure-driven, valve-gated delivery mechanism to deliver boluses of medication into the intrathecal space.

Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in October 2019, Haselmeier, a manufacturer of self-injection devices, partnered with Stevanato Group, a producer of glass primary packaging based in Italy, for development, manufacturing, and supply of the axis-D pen-injector in the therapeutic area of diabetes care.

Drug device combination products consists of drugs administered or delivered through a specialized devices to the patients. Examples of such products include prefilled syringes, infusion pumps, drug coated devices such as stents, and others. Manufacturers such as Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, and others offer drug device combination products in the market.

Restraints of the Global Drug-Device Combination Products Market

Major factors hampering the growth of the drug-device combination products market during the forecast period constitutes of presence of stringent and non-specific regulatory pathway and risks associated with infections.

Key features of the study:

  • This report provides in-depth analysis of the global drug-device combination products market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global drug-device combination products market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global drug-device combination products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Drug-Device Combination Products Market, By Product Type:
    • Drug Eluting Stents
      • Coronary stent
      • Peripheral Vascular stents
    • Infusion pumps
      • Implantable
      • Ambulatory
    • Photosensitizers
    • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
    • Wound care combination products
    • Inhalers
      • Nebulizers
      • MDI
      • DPI
    • Transdermal patches
    • Others( Intraocular implants, drug eluting beads)
  • Global Drug-Device Combination Products Market, By Geography:
    • North America
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Drug Eluting Stents
          • Coronary stent
          • Peripheral Vascular stents
        • Infusion pumps
          • Implantable
          • Ambulatory
        • Photosensitizers
        • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
        • Wound care combination products
        • Inhalers
          • Nebulizers
          • MDI
          • DPI
        • Transdermal patches
        • Others( Intraocular implants, drug eluting beads
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Becton, Dickinson and Company
    • Integer Holdings Corporation
    • Abbott Laboratories
    • Medtronic plc
    • Allergan, Inc.
    • Alcon, Inc.
    • Arrow International, Inc.
    • Bausch & Lomb, Inc.
    • Boston Scientific Corporation
    • Other Major Players

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Drug-Device Combination Products Market, By Product Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Drug Eluting Stents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Coronary stent
        • Peripheral Vascular stents
    • Infusion pumps
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Implantable
        • Ambulatory
    • Photosensitizers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Wound care combination products
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Inhalers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Nebulizers
        • MDI
        • DPI
    • Transdermal patches
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Others( Intraocular implants, drug eluting beads)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Drug-Device Combination Products Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Becton, Dickinson and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Integer Holdings Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Medtronic plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Alcon, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Arrow International, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bausch & Lomb, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boston Scientific Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Other Major Players
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 26 figures on “Drug-Device Combination Products Market – Global forecast to 2027.

Frequently Asked Questions

The global drug-device combination products market was valued at US$ 115.0 Bn in 2019 and is forecast to reach a value of US$ 214.1 Bn by 2027 at a CAGR of 8.1% between 2020 and 2027.
Major factor driving the growth of global drug-device combination products market during the forecast period increasing prevalence of chronic diseases, and product launches.
Major factors hampering the growth of the drug-device combination products market during the forecast period constitutes of presence of stringent and non-specific regulatory pathway and risks associated with infections.
Transdermal patches held dominant position in the global drug-device combination products market in 2019.
North America Drug-Device Combination Products market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner